Novartis AG
NVS · NYSE
Analyst Consensus
Hold
Analyst Ratings Synthesis
The supplied consensus is Hold from 11 analysts, with a mean price target of $147; the low and high targets are not available, so target clustering and the width of the spread cannot be measured. The evidence does not identify the most or least bullish analyst, nor does it provide named analyst-level target rankings. The direction of revisions over the past week appears negative because Deutsche Bank downgraded Novartis, although the snippet gives neither the prior nor new rating or target. The substantive disagreement is therefore between the mean target’s implied recovery case and concerns about trial failures, acquisition oversight, governance risk and dividend sustainability.
- Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
- Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
- NVS Looks 5.3% Overvalued on GF Value™ Amid Dividend Sustainabil
- Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
- NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul
Rating Actions
No individual rating actions have been captured for NVSyet. Consensus figures above come from Nasdaq's aggregate feed.
Research Reports
- Novartis's $30 Billion Deal Spree Triggers a Boardroom Reckoning
- Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
- Novartis Rebounds as $30 Billion Wipeout Draws Board Challenge
- NVS Stock On Track For Worst Week In Over 7 Years After Two Trial Failures In A Week — Investor Reportedly Seeks Board Overhaul
- Novartis facing board change threat from shareholder following trial failures (NVS:NYSE)
- Novartis stock downgraded at Deutsche Bank (NVS:NYSE)
- Novartis AG (NVS) Shares Fall 13.9% -- GF Value Says Still Overvalued
- Novartis Trial Failure Sparks Biopharma Options Frenzy
